Key Insights

Highlights

Success Rate

81% trial completion

Published Results

119 trials with published results (15%)

Research Maturity

394 completed trials (51% of total)

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 72/100

Termination Rate

11.7%

90 terminated out of 769 trials

Success Rate

81.4%

-5.1% vs benchmark

Late-Stage Pipeline

6%

45 trials in Phase 3/4

Results Transparency

30%

119 of 394 completed with results

Key Signals

119 with results81% success90 terminated

Data Visualizations

Phase Distribution

632Total
Not Applicable (107)
Early P 1 (18)
P 1 (218)
P 2 (244)
P 3 (42)
P 4 (3)

Trial Status

Completed394
Recruiting120
Terminated90
Unknown71
Active Not Recruiting44
Not Yet Recruiting22

Trial Success Rate

81.4%

Benchmark: 86.5%

Based on 394 completed trials

Clinical Trials (769)

Showing 20 of 20 trials
NCT01875601Phase 1Completed

NK White Blood Cells and Interleukin in Children and Young Adults With Advanced Solid Tumors

NCT03628209Phase 1Active Not Recruiting

Nivolumab or Nivolumab and Azacitidine in Patients With Recurrent, Resectable Osteosarcoma

NCT00579566RecruitingPrimary

Novel Biochemical and Molecular Determinants for Soft Tissue Sarcoma

NCT01109394RecruitingPrimary

Comprehensive Omics Analysis of Pediatric and Adult Solid Tumors and Establishment of a Repository for Related Biological Studies

NCT07089992Phase 2RecruitingPrimary

A Study of Pembrolizumab in People With Ultra-Rare Sarcomas

NCT02390752Phase 1Recruiting

Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...

NCT07725380Phase 1RecruitingPrimary

Domatinostat With Sirolimus for Relapsed, Refractory Sarcoma and Osteosarcoma

NCT06910657Phase 1Recruiting

IDOV-Immune for Advanced Solid Tumors

NCT06958107RecruitingPrimary

LCI-SAR-BSTS-CTDNA-001: Circulating Tumor DNA Liquid Biopsy in Sarcoma Patients

NCT06073067Not ApplicableRecruitingPrimary

GRID Therapy for Extremity Soft Tissue Sarcoma

NCT02298959Phase 1Active Not Recruiting

Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer

NCT03282344Phase 2Active Not RecruitingPrimary

A Study of NKTR-214 in Combination With Nivolumab in Patients With Metastatic and/or Locally Advanced Sarcoma

NCT07124000Recruiting

DESTINY-PANTUMOUR04

NCT06975293Phase 1Recruiting

STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas

NCT06904365Active Not Recruiting

Ovarian-Sparing Adaptive Radiotherapy in Young Adult Women

NCT04457258Early Phase 1Active Not Recruiting

68Ga-FAPi-46 PET/CT Scan in Imaging Patients With Sarcoma

NCT03069378Phase 2Active Not RecruitingPrimary

A Study of Talimogene Laherparepvec (T-VEC) in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma

NCT03261544RecruitingPrimary

Abductor Reattachment Methods in Proximal Femur Replacements: What is the Best Method?

NCT07389525Early Phase 1Not Yet Recruiting

Immune Checkpoint Inhibitor (ICI)-Drug-Drug Interaction (DDI) Study

NCT07602777Phase 1RecruitingPrimary

A Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Advanced Sarcomas (EMBOLD Sarcoma-202)

Scroll to load more

Research Network

Activity Timeline